ETIB Clinical Trials

ETIB 临床试验

• 批准号: 10702441
• 负责人: Ronald Gress
• 金额: $ 333.48万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10702441
• 关键词: Adult; Autologous; Bronchiolitis Obliterans; Clinical; Clinical Trials; Disease remission; Failure; Frequencies; Graft Rejection; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Immune system; Interferons; Joints; Laboratory Finding; Logistic Regressions; Modeling; Musculoskeletal; Nature; Patients; Phase; Publishing; Refractory; Relapse; Serology; Symptoms; Syndrome; Systemic Lupus Erythematosus; barrier to care; base; chronic graft versus host disease; cohort; genetic signature; graft vs host disease; hematopoietic cell transplantation; montelukast; reconstitution; tumor

This year we published our phase II results, that suggest montelukast may safely halt the progression of bronchiolitis obliterans syndrome which is a severe manifestation of chronic graft-versus-host disease (cGVHD) following hematopoietic cell transplantation. In a collaborative study, we found a high frequency of musculoskeletal symptoms in a cohort of adult patients with cGVHD. The multivariable logistic regression models showed that a joint set of factors were moderately well associated with musculoskeletal symptoms in this study. In addition, we found durable clinical and serologic remissions with suppression in the IFN gene signature can be achieved in refractory systemic lupus erythematosus (SLE) following lymphodepleting autologous haematopoietic cell transplantation (AHSCT).

今年我们发表了我们的第二阶段研究结果，表明孟鲁司特可以安全地阻止闭塞性毛细支气管炎综合征的进展，这是造血细胞移植后慢性移植物抗宿主病(CGVHD)的严重表现。在一项合作研究中，我们发现cGVHD成年患者中肌肉骨骼症状的频率很高。多变量Logistic回归模型显示，在本研究中，一组联合因素与肌肉骨骼症状有较好的相关性。此外，我们发现在难治性系统性红斑狼疮(SLE)患者接受淋巴清除自体造血细胞移植(AHSCT)后，干扰素基因信号被抑制的持续临床和血清学缓解是可以实现的。